The study was one of 11 highlighting Zimmer Biomet’s spine portfolio.
The winning study used seven-year data to show patients who received a total disc replacement with Mobi-C experienced less radiographic adjacent segment pathology than those receiving anterior cervical discectomy and fusion for both one and two levels.
A second study on Mobi-C was nominated for the Best Clinical Paper Award at the meeting. The study revealed total disc replacement patients treated with Mobi-C fared better than patients who underwent anterior cervical discectomy and fusion.
Zimmer Biomet Global Spine General Manager Joe Ross said, “The selection of multiple presentations, including four podium, six oral and one poster, from Zimmer Biomet Spine showcased at this year’s ISASS annual meeting underscores our steadfast commitment to advancing the clinical development and innovations of our entire spine portfolio.”
More articles on devices:
Meshplate device may replace metal implants — 4 key notes
Medtronic sells medical products business for $6.1B — 6 takeaways
Implanet revenue up 3% in Q1: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
